Published in PLoS One on December 28, 2012
Balancing the innate immune system in tumor development. Trends Cell Biol (2014) 0.98
CD56 marks human dendritic cell subsets with cytotoxic potential. Oncoimmunology (2013) 0.93
Interleukin-15 Dendritic Cells Harness NK Cell Cytotoxic Effector Function in a Contact- and IL-15-Dependent Manner. PLoS One (2015) 0.83
Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy. Front Immunol (2015) 0.82
Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy. Hum Vaccin Immunother (2013) 0.82
Interferon α may be back on track to treat acute myeloid leukemia. Oncoimmunology (2013) 0.79
Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation. Oncoimmunology (2015) 0.78
Interleukin-7 and interleukin-15 for cancer. J Cancer (2014) 0.78
HPV vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against HPV-positive tumour cells. J Cell Mol Med (2014) 0.77
Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8α dendritic cells. Cancer Immunol Immunother (2014) 0.77
Should EMT of Cancer Cells Be Understood as Epithelial-Myeloid Transition? J Cancer (2014) 0.77
Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity. Oncotarget (2015) 0.76
Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells. J Hematol Oncol (2016) 0.76
Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells. Oncotarget (2017) 0.75
Immune Cells in Cancer Therapy and Drug Delivery. Mediators Inflamm (2016) 0.75
PIAS1 and STAT-3 impair the tumoricidal potential of IFN-γ-stimulated mouse dendritic cells generated with IL-15. Eur J Immunol (2014) 0.75
CD56 in the Immune System: More Than a Marker for Cytotoxicity? Front Immunol (2017) 0.75
Dendritic cells: features and functions. Immunol Rev (1980) 6.34
Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol (1997) 5.48
Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 5.37
Dendritic cell immunotherapy: mapping the way. Nat Med (2004) 4.28
A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis. J Exp Med (1996) 3.66
Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med (2006) 3.49
A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med (2006) 3.21
Human NKR-P1A. A disulfide-linked homodimer of the C-type lectin superfamily expressed by a subset of NK and T lymphocytes. J Immunol (1994) 2.69
Functionally distinct subsets of human NK cells and monocyte/DC-like cells identified by coexpression of CD56, CD7, and CD4. Blood (2009) 2.43
Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med (2007) 2.20
Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J Exp Med (1989) 2.17
Delivering the kiss of death: progress on understanding how perforin works. Curr Opin Immunol (2007) 1.91
Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med (1999) 1.88
Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med (2012) 1.87
Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells. J Exp Med (2001) 1.85
Human natural killer cell development and biology. Blood Rev (2005) 1.83
CD11cloB220+ interferon-producing killer dendritic cells are activated natural killer cells. J Exp Med (2007) 1.82
Development and function of murine B220+CD11c+NK1.1+ cells identify them as a subset of NK cells. J Exp Med (2007) 1.76
Granzyme B induces smooth muscle cell apoptosis in the absence of perforin: involvement of extracellular matrix degradation. Arterioscler Thromb Vasc Biol (2004) 1.75
Mutual activation of natural killer cells and monocytes mediated by NKp80-AICL interaction. Nat Immunol (2006) 1.74
Human natural killer cell adhesion molecules. Differential expression after activation and participation in cytolysis. J Immunol (1990) 1.74
Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression. J Immunol (2000) 1.68
Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Invest (2012) 1.66
Natural killer cells: from CD3(-)NKp46(+) to post-genomics meta-analyses. Curr Opin Immunol (2007) 1.65
Retracted Novel APC-like properties of human NK cells directly regulate T cell activation. J Clin Invest (2004) 1.58
Perforin pores in the endosomal membrane trigger the release of endocytosed granzyme B into the cytosol of target cells. Nat Immunol (2011) 1.57
Putative IKDCs are functionally and developmentally similar to natural killer cells, but not to dendritic cells. J Exp Med (2007) 1.49
IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL. Eur J Immunol (2007) 1.45
Natural killer dendritic cells have both antigen presenting and lytic function and in response to CpG produce IFN-gamma via autocrine IL-12. J Immunol (2005) 1.43
T cell killing by tolerogenic dendritic cells protects mice from allergy. J Clin Invest (2011) 1.41
Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia (2012) 1.36
Natural killer or dendritic: what's in a name? Immunity (2007) 1.32
Isopentenyl pyrophosphate-activated CD56+ {gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. Clin Cancer Res (2008) 1.32
CD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions. J Immunol (2009) 1.23
Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities. Blood (2012) 1.23
Activation-induced expression of CD56 by T cells is associated with a reprogramming of cytolytic activity and cytokine secretion profile in vitro. Hum Immunol (2006) 1.16
Tumoricidal potential of native blood dendritic cells: direct tumor cell killing and activation of NK cell-mediated cytotoxicity. J Immunol (2005) 1.12
Killer dendritic cells and their potential for cancer immunotherapy. Cancer Immunol Immunother (2009) 1.10
IFN-alpha skews monocytes into CD56+-expressing dendritic cells with potent functional activities in vitro and in vivo. J Immunol (2008) 1.09
Granzyme B is expressed in mouse mast cells in vivo and in vitro and causes delayed cell death independent of perforin. Cell Death Differ (2007) 1.08
TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-α-mediated antitumor reactivity. J Immunol (2012) 1.06
Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties. J Transl Med (2009) 1.05
Plasmacytoid dendritic cells (pDCs) from HIV controllers produce interferon-α and differentiate into functional killer pDCs under HIV activation. J Infect Dis (2012) 1.04
Dendritic cell-based cancer gene therapy. Hum Gene Ther (2009) 1.02
A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. J Immunother (2012) 1.02
Killer dendritic cells: mechanisms of action and therapeutic implications for cancer. Cell Death Differ (2007) 1.02
Interferon-α in acute myeloid leukemia: an old drug revisited. Leukemia (2011) 1.01
Control of CD56 expression and tumor cell cytotoxicity in human Vgamma2Vdelta2 T cells. BMC Immunol (2009) 1.00
Dendritic cells as killers: mechanistic aspects and potential roles. J Immunol (2008) 0.99
IL-15 drives neonatal T cells to acquire CD56 and become activated effector cells. Blood (2003) 0.97
Monocytes differentiated with GM-CSF and IL-15 initiate Th17 and Th1 responses that are contact-dependent and mediated by IL-15. J Leukoc Biol (2011) 0.96
The 'kiss of death' by dendritic cells to cancer cells. Cell Death Differ (2007) 0.96
Dendritic cell vaccine therapy for acute myeloid leukemia: questions and answers. Hum Vaccin (2011) 0.93
Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells. Clin Cancer Res (2001) 0.93
IL-15 activated human peripheral blood dendritic cell kill allogeneic and xenogeneic endothelial cells via apoptosis. Cytokine (2012) 0.91
IL-15 induces CD8+ T cells to acquire functional NK receptors capable of modulating cytotoxicity and cytokine secretion. Immunobiology (2010) 0.91
Dendritic cell vaccination in acute myeloid leukemia. Cytotherapy (2012) 0.91
Human dendritic cell mediated cytotoxicity against breast carcinoma cells in vitro. J Leukoc Biol (2002) 0.89
Th-1 lymphocytes induce dendritic cell tumor killing activity by an IFN-γ-dependent mechanism. J Immunol (2011) 0.87
Poly(I:C) enhances the susceptibility of leukemic cells to NK cell cytotoxicity and phagocytosis by DC. PLoS One (2011) 0.87
Cytotoxic activity of human dendritic cells is differentially regulated by double-stranded RNA and CD40 ligand. J Immunol (2001) 0.87
Connecting the dots: monocyte/DC and NK subsets in human peripheral blood. Blood (2010) 0.85
In vitro growth inhibition of a broad spectrum of tumor cell lines by activated human dendritic cells. Blood (2000) 0.82
[Dendritic cell-based therapeutic vaccination for acute myeloid leukemia]. Bull Cancer (2012) 0.76
The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif (2003) 4.68
Dendritic cell immunotherapy: mapping the way. Nat Med (2004) 4.28
Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol (2007) 3.42
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol (2012) 1.97
Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest (2011) 1.91
Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A (2010) 1.84
Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production. Blood (2008) 1.79
Prognostic significance and mechanism of Treg infiltration in human brain tumors. J Neuroimmunol (2010) 1.70
Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother (2010) 1.60
Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med (2010) 1.60
Cell cycle and apoptosis. Cell Prolif (2003) 1.59
Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood (2005) 1.57
(19)F MRI for quantitative in vivo cell tracking. Trends Biotechnol (2010) 1.49
The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist (2008) 1.47
Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. Clin Cancer Res (2010) 1.45
Apoptosis: mechanisms and relevance in cancer. Ann Hematol (2005) 1.44
Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells. J Leukoc Biol (2007) 1.44
Sensitivity of magnetic resonance imaging of dendritic cells for in vivo tracking of cellular cancer vaccines. Int J Cancer (2007) 1.42
mRNA-based gene transfer as a tool for gene and cell therapy. Curr Opin Mol Ther (2007) 1.40
Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res (2013) 1.35
Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol (2012) 1.34
The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells. Blood (2012) 1.34
Toll-like receptor signalling on Tregs: to suppress or not to suppress? Immunology (2008) 1.33
Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res (2011) 1.29
Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res (2009) 1.24
Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities. Blood (2012) 1.23
Functional assessment of human dendritic cells labeled for in vivo (19)F magnetic resonance imaging cell tracking. Cytotherapy (2010) 1.23
DCIR is endocytosed into human dendritic cells and inhibits TLR8-mediated cytokine production. J Leukoc Biol (2008) 1.22
Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets. Blood (2012) 1.21
Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3'-fluoro-3'-deoxy-thymidine ([18F]FLT) PET imaging. Proc Natl Acad Sci U S A (2011) 1.19
Customizable, multi-functional fluorocarbon nanoparticles for quantitative in vivo imaging using 19F MRI and optical imaging. Biomaterials (2010) 1.18
Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro Oncol (2008) 1.15
Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunol Immunother (2008) 1.15
Regulatory T cells and human disease. Clin Dev Immunol (2007) 1.12
Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clin Cancer Res (2012) 1.11
Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr Opin Immunol (2005) 1.11
Maximizing dendritic cell migration in cancer immunotherapy. Expert Opin Biol Ther (2008) 1.11
Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial. Cytotherapy (2009) 1.09
Targeting uptake receptors on human plasmacytoid dendritic cells triggers antigen cross-presentation and robust type I IFN secretion. J Immunol (2013) 1.09
Flow cytometric detection of endothelial microparticles (EMP): effects of centrifugation and storage alter with the phenotype studied. Thromb Res (2010) 1.09
Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. Blood (2010) 1.07
Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials. Oncologist (2012) 1.07
Antigen cross-presentation by dendritic cell subsets: one general or all sergeants? Trends Immunol (2013) 1.05
Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties. J Transl Med (2009) 1.05
Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor. Clin Cancer Res (2005) 1.05
Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. Cancer Immunol Immunother (2010) 1.04
Plasmacytoid dendritic cells of melanoma patients present exogenous proteins to CD4+ T cells after Fc gamma RII-mediated uptake. J Exp Med (2006) 1.03
Dendritic cell-based cancer gene therapy. Hum Gene Ther (2009) 1.02
Human plasmacytoid dendritic cells phagocytose, process, and present exogenous particulate antigen. J Immunol (2010) 1.02
In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients. Cancer Res (2009) 1.02
A novel (19)F agent for detection and quantification of human dendritic cells using magnetic resonance imaging. Int J Cancer (2010) 1.01
Quantification of circulating endothelial progenitor cells: a methodological comparison of six flow cytometric approaches. J Immunol Methods (2008) 1.01
Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera. Platelets (2004) 1.01
Simultaneous activation of viral antigen-specific memory CD4+ and CD8+ T-cells using mRNA-electroporated CD40-activated autologous B-cells. J Immunother (2006) 0.99
Reporter gene-expressing bone marrow-derived stromal cells are immune-tolerated following implantation in the central nervous system of syngeneic immunocompetent mice. BMC Biotechnol (2009) 0.98
Clinical potential of intravenous neural stem cell delivery for treatment of neuroinflammatory disease in mice? Cell Transplant (2010) 0.98
NK cells: key to success of DC-based cancer vaccines? Oncologist (2012) 0.98
Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins. Blood (2005) 0.98
The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells. Cancer Immunol Immunother (2009) 0.97
Current challenges for the advancement of neural stem cell biology and transplantation research. Stem Cell Rev (2012) 0.96
Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells. Clin Cancer Res (2013) 0.96
Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial. Anticancer Res (2013) 0.96
Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma. Anticancer Res (2010) 0.95
Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study. J Immunother (2002) 0.95
Harnessing human plasmacytoid dendritic cells as professional APCs. Cancer Immunol Immunother (2012) 0.94
DEC-205 mediates antigen uptake and presentation by both resting and activated human plasmacytoid dendritic cells. Eur J Immunol (2011) 0.94
Phenotypic spectrum of dynamin 2 mutations in Charcot-Marie-Tooth neuropathy. Brain (2009) 0.94
Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR. Int J Cancer (2007) 0.93
Dendritic cell vaccine therapy for acute myeloid leukemia: questions and answers. Hum Vaccin (2011) 0.93
Messenger RNA electroporation of human monocytes, followed by rapid in vitro differentiation, leads to highly stimulatory antigen-loaded mature dendritic cells. J Immunol (2002) 0.93
CD56 marks human dendritic cell subsets with cytotoxic potential. Oncoimmunology (2013) 0.93
Immunotherapy of acute myeloid leukemia: current approaches. Oncologist (2009) 0.92
Intratumoral rhIL-12 administration in head and neck squamous cell carcinoma patients induces B cell activation. Int J Cancer (2008) 0.92
Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters. Cancer Immunol Immunother (2012) 0.92
Relevance of DC-SIGN in DC-induced T cell proliferation. J Leukoc Biol (2006) 0.91
Dendritic cell vaccination in acute myeloid leukemia. Cytotherapy (2012) 0.91
The nature of activatory and tolerogenic dendritic cell-derived signal II. Front Immunol (2013) 0.91
Naturally circulating dendritic cells to vaccinate cancer patients. Oncoimmunology (2013) 0.91
Prophylactic vaccines mimic synthetic CpG oligonucleotides in their ability to modulate immune responses. Mol Immunol (2011) 0.91
Crosstalk between dendritic cell subsets and implications for dendritic cell-based anticancer immunotherapy. Expert Rev Clin Immunol (2014) 0.91
Plasmid-based genetic modification of human bone marrow-derived stromal cells: analysis of cell survival and transgene expression after transplantation in rat spinal cord. BMC Biotechnol (2007) 0.90
Polyinosinic polycytidylic acid prevents efficient antigen expression after mRNA electroporation of clinical grade dendritic cells. Cancer Immunol Immunother (2008) 0.90
Probing cellular heterogeneity in cytokine-secreting immune cells using droplet-based microfluidics. Lab Chip (2013) 0.90
Deciphering the message broadcast by tumor-infiltrating dendritic cells. Am J Pathol (2012) 0.90
STATing the importance of immune modulation by platinum chemotherapeutics. Oncoimmunology (2012) 0.89
Dominant processes during human dendritic cell maturation revealed by integration of proteome and transcriptome at the pathway level. J Proteome Res (2010) 0.89
Regulation of MYCN expression in human neuroblastoma cells. BMC Cancer (2009) 0.89
mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. AIDS (2012) 0.88
Unraveling the human dendritic cell phagosome proteome by organellar enrichment ranking. J Proteomics (2011) 0.88
Allogeneic stromal cell implantation in brain tissue leads to robust microglial activation. Immunol Cell Biol (2009) 0.87